The need for post-operative vasopressor infusions after major gynae-oncologic surgery within an ERAS (Enhanced Recovery After Surgery) pathway.
Anaesthesia
Cancer surgery
Gynaecological oncology
Peri-operative medicine
Shock
Vasoconstrictors
Vasoplegia
Vasopressors
Journal
Perioperative medicine (London, England)
ISSN: 2047-0525
Titre abrégé: Perioper Med (Lond)
Pays: England
ID NLM: 101609072
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
01
2020
accepted:
24
08
2020
entrez:
17
9
2020
pubmed:
18
9
2020
medline:
18
9
2020
Statut:
epublish
Résumé
Hypotension following major abdominal surgery is common, and once hypovolaemia has been optimally treated, is often due to vasodilation which can be treated with vasopressor infusions. There is unpredictability in the dose and duration of post-operative vasopressor infusions, and factors associated with this have not been determined. We present a case series of consecutive patients who received major gynae-oncology surgery delivered within an Enhanced Recovery After Surgery (ERAS) pathway at a single institution. Patients were electively admitted from theatre directly to the intensive care unit (ICU). Data was collected prospectively into electronic databases (Philips ICCA, Wardwatcher) and then retrospectively collated and appropriate statistical analyses were performed. In the absence of a consensus definition of vasoplegia, we, necessarily arbitrarily, chose a noradrenaline dose of > 0.1 mcg/kg/min at 08:00 on the first post-operative day. The rationale is that this would be more than would typically be expected to counteract the vasodilatory effects of epidural analgesia, which is commonly used at our institution. Data was collected from 324 patients, all treated between February 2014 and July 2016. The average age was 67 years and 39% received neoadjuvant chemotherapy. The commonest tumour type was ovarian (58%). The median estimated blood loss was 800 ml and epidural analgesia was used in 71%. Fifty per cent received post-operative vasopressor infusions: factors associated with this included epidural use and estimated blood loss. Nineteen per cent met our criteria for vasoplegia: factors associated with this included CRP on post-operative day 1 and P-POSSUM morbidity score. Hospital and ICU length of stay was prolonged in those who had vasoplegia. Patients commonly receive vasopressors following major gynae-oncologic surgery, and this can be at relatively high doses. Clinical factors only accounted for a minority of the variability in vasopressor usage-suggesting considerable biological variability. Optimal care of patients having major abdomino-pelvic surgery may include advanced haemodynamic monitoring and ready availability of infused vasopressors, in a suitable environment.
Sections du résumé
BACKGROUND
BACKGROUND
Hypotension following major abdominal surgery is common, and once hypovolaemia has been optimally treated, is often due to vasodilation which can be treated with vasopressor infusions. There is unpredictability in the dose and duration of post-operative vasopressor infusions, and factors associated with this have not been determined.
METHODS
METHODS
We present a case series of consecutive patients who received major gynae-oncology surgery delivered within an Enhanced Recovery After Surgery (ERAS) pathway at a single institution. Patients were electively admitted from theatre directly to the intensive care unit (ICU). Data was collected prospectively into electronic databases (Philips ICCA, Wardwatcher) and then retrospectively collated and appropriate statistical analyses were performed. In the absence of a consensus definition of vasoplegia, we, necessarily arbitrarily, chose a noradrenaline dose of > 0.1 mcg/kg/min at 08:00 on the first post-operative day. The rationale is that this would be more than would typically be expected to counteract the vasodilatory effects of epidural analgesia, which is commonly used at our institution.
RESULTS
RESULTS
Data was collected from 324 patients, all treated between February 2014 and July 2016. The average age was 67 years and 39% received neoadjuvant chemotherapy. The commonest tumour type was ovarian (58%). The median estimated blood loss was 800 ml and epidural analgesia was used in 71%. Fifty per cent received post-operative vasopressor infusions: factors associated with this included epidural use and estimated blood loss. Nineteen per cent met our criteria for vasoplegia: factors associated with this included CRP on post-operative day 1 and P-POSSUM morbidity score. Hospital and ICU length of stay was prolonged in those who had vasoplegia.
CONCLUSIONS
CONCLUSIONS
Patients commonly receive vasopressors following major gynae-oncologic surgery, and this can be at relatively high doses. Clinical factors only accounted for a minority of the variability in vasopressor usage-suggesting considerable biological variability. Optimal care of patients having major abdomino-pelvic surgery may include advanced haemodynamic monitoring and ready availability of infused vasopressors, in a suitable environment.
Identifiants
pubmed: 32939254
doi: 10.1186/s13741-020-00158-0
pii: 158
pmc: PMC7487584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
JAMA. 2014 Jun 4;311(21):2181-90
pubmed: 24842135
Br J Anaesth. 2016 May;116(5):586-9
pubmed: 27106961
Crit Care. 2017 Jun 12;21(1):141
pubmed: 28602158
Intensive Crit Care Nurs. 2017 Aug;41:104-108
pubmed: 28343834
Crit Care. 2018 Jul 6;22(1):174
pubmed: 29980217
Intensive Care Med. 2016 Jul;42(7):1176-8
pubmed: 26932348
Curr Opin Crit Care. 2006 Aug;12(4):325-32
pubmed: 16810043
Am J Respir Crit Care Med. 2019 May 1;199(9):1097-1105
pubmed: 30704260
Br J Anaesth. 2019 May;122(5):575-586
pubmed: 30916008
Medicine (Baltimore). 2015 Dec;94(49):e2108
pubmed: 26656336
Gynecol Oncol. 2016 Feb;140(2):313-22
pubmed: 26603969
Crit Care. 2013 Apr 17;17(2):R72
pubmed: 23594407
Arch Surg. 2006 Nov;141(11):1132-40
pubmed: 17116807
J Intensive Care. 2016 Apr 16;4:27
pubmed: 27087980
Gynecol Oncol. 2016 Feb;140(2):323-32
pubmed: 26757238
JAMA. 2017 Oct 10;318(14):1346-1357
pubmed: 28973220
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708